At Ayala, we are dedicated to developing targeted therapies specifically for patients living with rare and aggressive diseases. In combination with next-generation sequencing and our proprietary bioinformatics platform, we are pioneering a novel approach to cancer treatment.
July 05, 2022
Ayala Pharmaceuticals Announces Interim Data from Part A of the Phase 2/3 RINGSIDE Trial of AL102 in Desmoid Tumors
June 06, 2022
Ayala Pharmaceuticals Announces Data on AL101 in Adenoid Cystic Carcinoma (ACC) at 2022 ASCO Annual Meeting